Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps is his Department taking to improve access to ADHD medication.

The Department of Health and Social Care has worked closely with industry stakeholders on this issue. Following extensive collaborative efforts, previous issues have been resolved and all strengths of lisdexamfetamine, atomoxetine capsules, atomoxetine oral solution, guanfacine prolonged-release tablets and methylphenidate prolonged-release tablets are now available.

We continue to support the NHS England ADHD taskforce, which brings together expertise from the NHS, education, and justice sectors to coordinate a system-wide response to rising demand. In collaboration with NHS England’s national ADHD data improvement plan, we are developing future growth forecasts to support improved demand planning. These forecasts will be shared with industry to help ensure a more responsive and sustainable supply of ADHD medicines.

In parallel, we are also engaging with new suppliers for ADHD medicines to increase supply capacity and resilience.

The Department also maintains and regularly updates a list of currently available and unavailable ADHD products on the Specialist Pharmacy Service (SPS) website. This resource supports prescribers and dispensers in making informed decisions with patients. The list is available at the following link: www.sps.nhs.uk/articles/prescribing-available-medicines-to-treat-adhd